1Jacobson P, Uberti J, Davis W, et al. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation.Bone Marrow Transplant, 1998,22:217-225.
3Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med, 1975,292:832-843.
4Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood, 1981,57:267-276.
5Uberti JP,Scalzo A,Hammelef K, et al. Allogeneic peripheral blood stem cell transplantation for hematologic malignancy: the efficacy of tacrolimus in the prevention of acute graft-versus-host disease. Blood, 1997,90:393b.
6Ratanatharathorn V, Nash RA,Przepiorka D, et al. Phase Ⅲ study comparing methotrexate and tacrolimus(Prograf, FK506)with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood, 1998, 92: 2303-2314.
7Kanamaru A, Takemoto Y, Kakishita E, et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant, 1995,15:885-889.
